Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension. Its technology involves endovascular catheters to provide an efficacious, durable, cost-effective, and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.
The company was founded in 2011 by Tim Fischell, MD, FACC, and David Fischell, Ph.D., to address this significant unmet medical need.
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people. The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations of adeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
Spire, Inc., also known as Spire Health, is a San Francisco-based company that develops health-tracking devices and remote patient monitoring solutions aimed at managing respiratory chronic diseases. Founded in 2013, Spire specializes in continuous respiration sensing and patient-friendly ambulatory monitoring. Its devices measure inhalation and exhalation patterns, steps, and calories, providing insights into daily activities and overall well-being through a mobile application. The company focuses on health conditions such as chronic obstructive pulmonary disease, congestive heart failure, asthma, sleep disorders, and anxiety. By leveraging advanced algorithms and sensors, Spire Health aims to empower both patients and healthcare providers with actionable data to improve health outcomes.
KLIFO provides end-to-end expert capabilities, enabling partners to maximise opportunity, mitigate risks, drive innovation and achieve efficient project advancement. The company offers multidisciplinary consulting and operational solutions spanning all clinical research areas, clinical trial supply, QA, CMC development, regulatory affairs, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices.
ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Acti-Med is a manufacturer in the field of medical technology. Acti-Med competence lies in the high-quality development and production of cannulas and cannula systems for medical technology and the pharmaceutical industry.
LUMICKS B.V. is a company that specializes in the manufacture of dynamic single-molecule analysis equipment, enabling researchers to visualize biological processes at the molecular level. The company offers advanced systems such as the C-Trap, which integrates optical tweezers with confocal microscopy or STED nanoscopy, as well as microfluidics solutions for single-molecule experiments. Its Acoustic Force Spectroscopy (AFS) technology allows scientists to examine the mechanical properties of biological systems using synthetic microspheres. Additionally, LUMICKS provides the u-Flux microfluidics system, designed for conducting experiments in a laminar flow environment. Founded in 2014 and headquartered in Amsterdam, the Netherlands, LUMICKS also has an office in Cambridge, Massachusetts, and operates consumables stores to support its instrumentation offerings. The company focuses on delivering cutting-edge technologies for studying biology and cancer at the single-molecule and single-cell levels.
Amphista Therapeutics operates as a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body's natural processes to selectively and efficiently degrade and remove disease causing proteins.
Volta Medical is a start-up based in Marseille, France, that specializes in developing artificial intelligence software for interventional cardiology, particularly focusing on the treatment of atrial fibrillation, the most common cardiac arrhythmia. Founded in 2016, the company has created AIFib, its first AI software that enhances the functionality of mapping catheters used in the analysis of electrograms and the treatment of arrhythmias. Volta Medical aims to provide innovative solutions that assist cardiologists during interventional procedures, embodying expertise in both interventional cardiology and intracardiac signal analysis. The company's commitment to advancing its technology and products is reflected in its efforts to recruit top talent and its recognition from the European Commission, which awarded its technology a "Seal of Excellence."
Noema Pharma is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapies for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts aim to address the most disabling symptoms associated with conditions such as Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By prioritizing patient needs, Noema Pharma seeks to create effective treatments that significantly improve the quality of life for individuals suffering from these challenging conditions.
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Eargo, Inc. is a consumer-focused medical device company based in San Jose, California, that specializes in developing and selling innovative hearing aids for individuals experiencing hearing loss. Founded in 2010, Eargo offers a range of rechargeable hearing aids that can be controlled via smartphone, addressing common barriers to hearing aid adoption such as cost, accessibility, and social stigma. The company provides online hearing screenings and virtual support, allowing customers to receive assistance without needing in-person visits. Eargo's products are available for purchase online or over the phone, and the company emphasizes personalized consultations with licensed hearing professionals through various communication channels. By offering its solutions at approximately half the cost of traditional hearing aids, Eargo aims to enhance the quality of life for people with hearing impairments.
Withings is a developer of digital health and wellness devices aimed at empowering individuals to make informed health decisions. The company offers a diverse range of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers, hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings provides medically accurate devices for monitoring blood pressure and temperature, allowing users to effectively track their health progress. These products facilitate data sharing with healthcare professionals, promoting a collaborative approach to personal health management.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries.
The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Big Health is a London-based company that develops and markets digital healthcare solutions focused on improving mental health and sleep disorders. Its flagship product, Sleepio, is a digital sleep improvement program that utilizes Cognitive Behavioral Therapy techniques to address individual sleep challenges. The platform offers fully-automated, personalized therapeutic sessions, allowing users to engage with their specific issues and track their progress. In addition to Sleepio, Big Health provides a broader digital healthcare portal that delivers customized behavioral programs aimed at various mental health concerns, all designed in consultation with medical professionals to ensure efficacy and relevance.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
SANIFIT is a biotechnology company focused on treatments for calcification disorders.
SANIFIT started activities in 2007 and has now operations in Spain and Switzerland.
CVRx is a medical device company that develops implantable technology for the treatment of high blood pressure. Its products include Rheos implantable pulse generator that provides control and delivery of the activation energy; and Rheos carotid sinus leads, which conducts activation energy from the Rheos implantable pulse generator to the left and right carotid arteries.
The company also offers a Rheos programmer system that communicates with the Rheos pulse generator. CVRx was founded in 2001 and is based in Minneapolis, Minnesota.
Vesper Medical, Inc., a medical device company, develops minimally invasive peripheral vascular products. It offer Vesper DUO Venous Stent System, built for venous stenting. The company was founded in 2016 and is based in Wayne, Pennsylvania.
Eetgemak BV, established in 2006 and located in Katwijk, the Netherlands, specializes in the production of ready-made meals tailored for various sectors, including healthcare and education. The company offers a diverse range of chilled and frozen meal options, including regular, biological, vegetarian, and multicultural dishes, as well as specialized dietary meals. Its clientele consists of hospitals, nursing homes, residential care centers, home care organizations, schools, daycare centers, and catering establishments. Eetgemak’s products are designed to support the nutritional needs and well-being of patients and residents, ensuring that meals are both convenient and health-conscious.
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension. Its technology involves endovascular catheters to provide an efficacious, durable, cost-effective, and safe alternative to surgical renal denervation for the treatment of hypertension and other diseases caused by an overactive sympathetic nervous system.
The company was founded in 2011 by Tim Fischell, MD, FACC, and David Fischell, Ph.D., to address this significant unmet medical need.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of hematological and solid cancers. Its platform creates and develops next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer as well as develop potent, safe, and cost-effective biopharmaceuticals that arm the immune system to recognize and destroy tumor cells that enable doctors to safely channel the immune system's response towards tumors.
Lava Therapeutics was established in 2016 and is headquartered in Utrecht, The Netherlands.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Inari Medical, Inc., a commercial-stage medical device company, focuses on developing products to treat and transform the lives of patients suffering from venous diseases in the United States. It produces ClotTriever for treatment of deep vein thrombosis; and FlowTriever, a thrombectomy system for treatment of pulmonary embolism. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was founded in 2011 and is headquartered in Irvine, California.
Performation Healthcare Intelligence is a provider of healthcare specific business intelligence solutions to monitor costs, processes and quality. The company supports clients in taking well-informed decisions that contribute to the delivery of high quality and effective care. With over a hundred enthusiastic consultants and business intelligence experts, Performation is a leading player in the Dutch market.
Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.
Axonics is a pre-revenue company developing novel implantable neuromodulation technology licensed from The Alfred Mann Foundation directed toward a number of clinical indications, including the treatment of chronic pain and overactive bladder.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Breath Therapeutics GmbH, based in Munich, Germany, with an additional office in Menlo Park, California, develops innovative drug-aerosol therapeutics aimed at treating bronchiolitis obliterans syndrome and other severe respiratory diseases. Founded in 2016 and now a subsidiary of Zambon S.p.A., the company focuses on combining novel formulations of existing drugs with advanced inhalation technologies. Their products include a liposomal formulation of cyclosporine A designed for inhalation, paired with a high-performance nebulizer that optimizes drug delivery. This approach allows for rapid delivery of high drug concentrations directly to the lungs, enhancing the efficacy of treatments while reducing systemic exposure. Breath Therapeutics aims to address significant unmet medical needs in rare pulmonary conditions through its targeted inhalation therapies.
LUMICKS B.V. is a company that specializes in the manufacture of dynamic single-molecule analysis equipment, enabling researchers to visualize biological processes at the molecular level. The company offers advanced systems such as the C-Trap, which integrates optical tweezers with confocal microscopy or STED nanoscopy, as well as microfluidics solutions for single-molecule experiments. Its Acoustic Force Spectroscopy (AFS) technology allows scientists to examine the mechanical properties of biological systems using synthetic microspheres. Additionally, LUMICKS provides the u-Flux microfluidics system, designed for conducting experiments in a laminar flow environment. Founded in 2014 and headquartered in Amsterdam, the Netherlands, LUMICKS also has an office in Cambridge, Massachusetts, and operates consumables stores to support its instrumentation offerings. The company focuses on delivering cutting-edge technologies for studying biology and cancer at the single-molecule and single-cell levels.
Nyxoah S.A. is a health-technology company based in Mont-Saint-Guibert, Belgium, focused on developing innovative solutions for treating sleep-disordered breathing, particularly obstructive sleep apnea (OSA). Founded in 2009, Nyxoah has created the Genio system, a CE-Mark validated bilateral neuro-stimulation therapy designed for patients with moderate to severe OSA. The company aims to improve the quality of life for OSA sufferers by offering a less cumbersome alternative to traditional devices and complex surgeries. Its technology features a tiny, battery-less implantable neurostimulator that targets the nerves of the tongue to prevent airway blockage, stimulating the muscles only when necessary. This approach not only reduces costs and simplifies implantation but also minimizes the risk of device migration. By collaborating with leading experts in sleep disorders, Nyxoah is dedicated to advancing neurostimulation devices that can significantly enhance the lives of those affected by OSA.
NightBalance B.V. develops and markets an obstructive sleep apnea (OSA) device for the treatment of positional obstructive sleep apnea to customers in Europe. It develops Sleep Position Trainer (SPT), which measures the sleep behavior of the patient continuously; gives a gentle vibration once the patient turns into the supine position; and reminds the patient to change their sleeping position without disrupting their natural sleeping architecture. The company was founded in 2009 and is based in The Hague, the Netherlands. As of May 8, 2018, NightBalance B.V. operates as a subsidiary of Koninklijke Philips N.V.
STAT-Dx Life S.L. is a Barcelona-based company that specializes in the development, manufacturing, and marketing of molecular diagnostic systems. Established in 2010, the company focuses on creating near-patient testing products aimed at providing timely and efficient patient care, particularly in critical care environments. Its flagship product, the DiagCORE, is a portable multi-analyte instrument designed for molecular and immunoassay testing across various clinical settings. STAT-Dx offers several diagnostic panels, including the DiagCORE Cartridge for syndrome testing, the DiagCORE Analyzer for modular analysis, and specific panels for respiratory, gastrointestinal, central nervous system, pneumonia, and blood culture identification. In 2018, STAT-Dx became a subsidiary of QIAGEN N.V., further enhancing its capabilities in the diagnostics field.
Private Equity Round in 2016
NIZO food research BV provides contract research and food innovation services for dairy, food and beverage, ingredients, and biotech industries worldwide. It offers analysis, contract research, production, Webinar, white paper, training, and pre-competitive research program services; and proteins, bacteria, and processing solutions. The company also rents a flex office. NIZO food research BV was founded in 1948 and is headquartered in Ede, the Netherlands with additional offices in the United States, France, and Japan.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
BiOM (fromerly iWalk) is a Massachusetts based company whose sole product is the PowerFoot One. The Powerfoot One has two powerful microprocessors and six environmental sensors evaluate and adjust ankle position, stiffness, damping and power thousands of times a second. Control algorithms generate human-like force while traversing level ground, slopes and stairs, providing active amputees with near-normal gait and lower energy expenditure compared to state-of-the-art passive prosthetics.
SANIFIT is a biotechnology company focused on treatments for calcification disorders.
SANIFIT started activities in 2007 and has now operations in Spain and Switzerland.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Zetacom is a systems integrator based in the Netherlands, specializing in communication solutions for healthcare institutions, government bodies, corporates, and small to medium enterprises. The company is a market leader in healthcare-specific communication systems, with approximately 25% of hospitals and care institutions in the country utilizing its services. Zetacom offers a range of products including business telephony, care alarm systems, voice over WLAN, mobile telephony, and Unified Communications. Additionally, it is involved in the installation and maintenance of network infrastructures, telecommunication systems, and network security solutions. With a workforce of 140 employees, Zetacom operates from its headquarters in Zoetermeer and a southern office in 's-Hertogenbosch, ensuring that it delivers reliable and cost-effective communication systems tailored to the needs of its clients.
Private Equity Round in 2015
Zetacom is a systems integrator based in the Netherlands, specializing in communication solutions for healthcare institutions, government bodies, corporates, and small to medium enterprises. The company is a market leader in healthcare-specific communication systems, with approximately 25% of hospitals and care institutions in the country utilizing its services. Zetacom offers a range of products including business telephony, care alarm systems, voice over WLAN, mobile telephony, and Unified Communications. Additionally, it is involved in the installation and maintenance of network infrastructures, telecommunication systems, and network security solutions. With a workforce of 140 employees, Zetacom operates from its headquarters in Zoetermeer and a southern office in 's-Hertogenbosch, ensuring that it delivers reliable and cost-effective communication systems tailored to the needs of its clients.
Lumeon Ltd. is a digital health company specializing in care pathway management solutions for the healthcare sector. Founded in 2005 and headquartered in London, the company offers a cloud-based platform known as the Care Pathway Manager, which provides a comprehensive, real-time view of the patient journey from referral to outcome. Lumeon's services encompass business analysis, project management, data migration, training, and ongoing support. By focusing on the entire care pathway, Lumeon aids healthcare providers in optimizing clinical and administrative workflows, automating tasks, and achieving measurable healthcare outcomes. The company serves a diverse range of clients, including some of Europe's leading healthcare organizations. Lumeon was previously known as Qinec Ltd. before rebranding in July 2016.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Private Equity Round in 2015
Novicare provides nursing homes the opportunity to outsource their (para) medical staff. Novicare works with multidisciplinary self-managed teams that boost the quality of the (para) medical care. Novicare treats clients with complex and chronic conditions. Novicare also offers care to people at home under its brand VitaalThuis. Finally, Novicare offers its expertise to nursing homes by providing education, interim management and consultancy.
Novicare employs geriatricians, psychologists, physiotherapists, occupational therapists, speech therapists and dieticians.
The services of Novicare are characterized by its expertise, transparency, well-defined products and a high involvement in the patients.
With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.
Levicept is an asset-centric UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. We are progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis.
AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries.
Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
Vapotherm, Inc. is a medical technology company based in Exeter, New Hampshire, specializing in the development and commercialization of proprietary Hi-VNI technology products designed to treat respiratory distress in patients of all ages. The company offers a range of Precision Flow systems, including Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox, which deliver heated, humidified, and oxygenated air at high velocity through small-bore nasal interfaces. Additionally, Vapotherm provides various companion products such as the Vapotherm Transfer Unit for patient mobility, the Q50 compressor for compressed air supply, and specialized adaptors and cannulas to enhance treatment delivery. The company also produces disposable patient circuits for aerosol nebulization and Oxygen Assist Modules to help maintain target oxygen levels. Vapotherm primarily sells its products to hospitals in the United States and through distributors in select international markets. Founded in 1993, Vapotherm aims to improve clinical outcomes and enhance the quality of life for patients.
Viroclinics Biosciences is a leading contract research and clinical laboratory service company providing diagnostic and preclinical studies along with drug development for prevention and treatment of virus infections. With our extensive experience in respiratory viruses, in particular influenza, our mission is to improve human and animal health by serving the biopharmaceutical community with state-of-the-art diagnostics, custom-made models in (pre)clinical drug testing, and expert advice on development of antivirals and vaccines. We offer a full range of virology services for new drug development programs and post-marketing surveillance of existing drugs and vaccines, ranging from traditional virology assays to the latest deep sequencing protocols for a very broad range of viruses. Our BSL2 and BSL3 labs enable us to perform analysis according to international ISO 15189 accreditation. Close cooperation with the Erasmus MC Viroscience lab brings the combined benefits of a broad range of knowledge, experience and skills to our work
Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Private Equity Round in 2012
Pharmaline is a young, innovative, semi-industrial compounding pharmacy, based in Oldenzaal. In 2009 they started with 30 employees; at this time that there are over 140. Their highly qualified company has been set up according to the latest GMP guidelines. They offer about 700 pharmacists in the Netherlands a rational and comprehensive range of pharmaceutical solutions, service and advice. Standardization, rationalization, knowledge and expertise are central, increasing the quality of care while reducing healthcare costs. Their mission is short and sweet: "Care for Saving lives and costs. Pharmaline offers the full package pharmacy compounding that is common in community pharmacies. This applies both to stock preparations as ad hoc preparations at the patient level in the form of creams, ointments, tablets, capsules, drops, liquids, suspensions, and injectabilia (injections, infusions, cassettes). You do not need to look where certain products are available; with us you can find all your pharmacy preparations! Their experienced pharmacists are daily available to advise you on rationality, pharmacotherapy, production engineering, application engineering and legislation. Of course they also have the most modern equipment.
Definiens is the provider of image analysis and data mining solutions for quantitative digital pathology in the life sciences, diagnostic biomarkers and healthcare industries.
Definiens software provides detailed readouts from whole tissue slides, cell-based assays and full body scans and allows correlating this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and supports better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.
Definiens is headquartered in Munich, Germany, and has offices throughout the United States.
BiOM (fromerly iWalk) is a Massachusetts based company whose sole product is the PowerFoot One. The Powerfoot One has two powerful microprocessors and six environmental sensors evaluate and adjust ankle position, stiffness, damping and power thousands of times a second. Control algorithms generate human-like force while traversing level ground, slopes and stairs, providing active amputees with near-normal gait and lower energy expenditure compared to state-of-the-art passive prosthetics.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
Private Equity Round in 2012
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
Moximed, Inc. is focused on developing joint-preserving solutions for patients suffering from knee osteoarthritis. The company's primary product, the Atlas System, functions as an implantable joint unloader, similar to a shock absorber, specifically targeting individuals experiencing pain in the medial compartment of the knee. This innovative approach aims to alleviate joint pain, reduce dynamic load, and potentially delay the necessity for more invasive surgical interventions. Moximed seeks to enhance the standard of care for osteoarthritis patients, helping them maintain an active lifestyle while serving both patients and medical professionals globally. Established in 2006 and headquartered in Hayward, California, Moximed was previously known as ExploraMed NC4, Inc.
Inova Labs, Inc. operates as a medical device development, manufacturing, and worldwide distribution company. It primarily focuses on direct patient care products. The company offers LifeChoice, a stationary and portable oxygen concentrator with a pulse mode system for patients requiring 1, 2, or 3LPM of supplemental oxygen; and accessories, including carrying cases, external batteries, and DC and AC power adapters. It sells its products through authorized providers on their Websites. The company was founded in 2002 and is based in Austin, Texas.
Private Equity Round in 2011
Fysius is a chain of clinics for patients with lower-back and related pains. The treatment methods and treatment aids, such as the OriGENE device, take advantage of the latest scientific insights. With over 10,000 treated patients annually, Fysius is the largest and most specialized clinic for back pain in the Netherlands.
ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004
Private Equity Round in 2011
VerzuimVitaal is a Dutch provider of occupational health services that help companies manage employee absenteeism. VerzuimVitaal reduces the costs of absenteeism by increasing the vitality of client organizations and their employees. It also manages the process of sick leave and reintegration.
Prosonix Ltd. operates as a specialty pharmaceutical company, which develops and markets a portfolio of inhaled respiratory medicines to treat asthma and chronic obstructive pulmonary diseases. It develops generic mono and combination therapies based on inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA); and dual and triple combination therapies for respiratory diseases based on its multiple-component particle technology. The company was founded in 2006 and is based in Oxford, United Kingdom. As of June 15, 2015, Prosonix Ltd. operates as a subsidiary of Circassia Limited.
Acacia Pharma is a hospital pharmaceutical company based in Cambridge, United Kingdom, that specializes in the discovery, development, and commercialization of supportive care drugs for patients undergoing surgery, invasive procedures, or cancer treatments. The company’s lead product, BAREMSIS, is an intravenous formulation of amisulpride designed to prevent and treat post-operative nausea and vomiting. Other notable products include APD403, which has completed Phase II trials for chemotherapy-induced nausea and vomiting, and BYFAVO, an ultra-short-acting intravenous benzodiazepine anesthetic that has completed Phase III trials for use in procedures like colonoscopy and bronchoscopy. Acacia Pharma primarily serves anesthesiologists and oncologists, with a focus on addressing issues related to nausea, vomiting, cancer-related fatigue, and cachexia. Established in 2006, the company continues to innovate in the field of cancer supportive care.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Private Equity Round in 2010
Stepping Stones & Home Care Ltd is the founder and owner of three small villas, residential care for demented and frail elderly who are no longer able to live independently.
mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
ProFibrix B.V., a biotech company, creates, develops, and markets products for the hemostasis and regenerative medicine markets. Its products include Fibrocaps, a dry powder topical hemostat and tissue sealant based on a mixture of fibrinogen and thrombin, which stops acute and severe bleeding during surgery or in connection with trauma injury. The company also provides a sterilized single-use delivery device to deliver Fibrocaps to the target tissue area without the need to manipulate the wound in a surgical environment. It offers its products based on human fibrinogen, a natural blood protein for haemostasis, blood clotting, and tissue repair and healing. ProFibrix B.V. was founded in 2004
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostic tests based on biomarkers for high-value market opportunities in healthcare that they identify.
Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combine the company’s proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of disease states. The company’s research and development activities focus on infectious diseases and cardiometabolic disorders, while partnerships with major pharmaceutical companies include a range of therapeutic areas including cancer, cardiovascular disease, infectious and inflammatory diseases, and rare genetic disorders. The company has strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline, and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds exclusive worldwide rights to manufacture, have manufactured and sell products that contain LNA as an active ingredient for studies performed with a view to obtaining marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark with operations in the United States.
FlowCardia, Inc. is a medical device company founded in 2002 to design and develop a portfolio of innovative, catheter-based technologies to facilitate guidewire crossing of totally occluded coronary and peripheral arteries. Chronic Total Occlusions (CTOs) are considered one of the last major clinical challenges in interventional therapy. The historic absence of safe and effective CTO recanalization devices is a major reason a large number of patients are still referred to coronary and peripheral bypass surgery and lower limb amputation.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Conatus Pharmaceuticals Inc. is a biotechnology company that specializes in developing innovative therapeutics for liver diseases and chronic conditions with significant unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company has focused on its lead product candidate, Emricasan, an orally active caspase protease inhibitor currently in Phase IIb clinical trials for various liver-related conditions, including post-orthotopic liver transplant complications and liver fibrosis linked to nonalcoholic steatohepatitis. Additionally, Conatus is advancing CTS-2090, an orally active inhibitor of caspase 1, which is in the preclinical stage for treating chronic diseases associated with inflammasome pathways. The company has also entered into a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. In May 2020, Conatus Pharmaceuticals was acquired by Histogen Inc. in a reverse merger transaction.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Agendia's molecular diagnostic technology provides cancer patients and their physicians with a glimpse into their genome, answers to the most pressing questions and enables personalized treatment plans. Agendia’s breast cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Agendia’s tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.
Chroma Therapeutics Ltd. develops novel small molecule drugs based on chromatin biology and novel cell accumulation approaches for targeted cancer and inflammation treatments. Its products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor for the treatment of cancer; and CHR-2845, a targeted solution for haemotological malignancies. The company was founded in 2000 and is based in Abingdon, United Kingdom.
Symphogen A/S is a late-stage biopharmaceutical company based in Ballerup, Denmark, with an operational presence in Somerville, New Jersey. The company specializes in developing innovative therapies for cancer and other significant diseases, focusing on recombinant polyclonal antibodies (rpAb). Its product pipeline includes Sym004, a mixture of two monoclonal antibodies targeting different epitopes of EGFR for metastatic colorectal cancer and glioblastoma; Sym013, which inhibits EGFR, HER2, and HER3; and Sym015, aimed at eliminating the MET receptor. Additionally, Sym021 is designed to block PD1, while Sym009 is a monoclonal antibody conjugated to an antibiotic for treating resistant strains of staphylococcus aureus. Symphogen targets various epithelial cancer indications, including colorectal, lung, brain, breast, pancreatic, and head and neck cancers. Founded in 2000, Symphogen continues to advance its mission in the biopharmaceutical sector.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Evotec is a global drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in various therapeutic areas, including neuroscience, diabetes, oncology, infectious diseases, and pain and inflammation. It offers a range of services such as fee-for-service drug discovery, integrated collaborations, and development partnerships, with a significant portion of its revenue generated from shared research and development activities. Evotec has established numerous long-term alliances with major industry players and is actively involved in both clinical and pre-clinical development programs. The company also operates a segment focused on biologics, providing contract development and manufacturing organization services. Through its expertise and advanced technologies, Evotec aims to deliver differentiated therapeutics and drive the progress of drug development across multiple fields.
Roche Glycart develops antibody drug candidates, which include GA101, a humanized anti-CD20 monoclonal antibody to increase direct- and immune-mediated target cell death; and GA201, a humanized glycoengineered antibody for solid tumors.
Pieris Pharmaceuticals is a clinical-stage biotechnology company that develops drugs to fight cancer, severe asthma, anemia, and other medical conditions with unmet medical needs. The company applies its proprietary Anticalin® technology to the drug development processes. Pieris Pharmaceuticals was founded in 2001 and is based in Freising, Bayern.
Ablynx NV is a clinical biopharmaceutical company based in Ghent, Belgium, that specializes in the discovery and development of Nanobodies, a novel class of therapeutic proteins derived from single-domain antibody fragments. The company focuses on addressing serious human diseases, including inflammation, hematology, oncology, and respiratory conditions. Ablynx has a diverse pipeline with approximately 25 projects, featuring five Nanobodies currently in clinical development. Notable clinical programs include caplacizumab for acquired thrombotic thrombocytopenic purpura, ALX-0171 for respiratory syncytial virus infection, and Vobarilizumab for rheumatoid arthritis and systemic lupus erythematosus. Other ongoing trials involve treatments for psoriasis, solid tumors, chronic kidney diseases, and bone-loss related disorders. Ablynx has established collaboration agreements with several major pharmaceutical companies to advance its research and development efforts. Founded in 2001, Ablynx was formerly known as MatchX and rebranded in 2002. The company operates as a subsidiary of Sanofi.
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.
The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.